Medicare's GLP-1 medication discount program raises significant concerns about eligibility criteria and access gaps. While these weight-loss drugs offer therapeutic benefits for cardiovascular and metabolic conditions, strict qualification requirements exclude many high-risk patients who would benefit most. This coverage limitation highlights the ongoing debate about pharmaceutical accessibility and the need for more inclusive healthcare policies that address patients with multiple comorbidities.

Summary auto-generated by AI from the original publisher's content. Editorial standards.